COSCIENS Biopharma (NASDAQ:CSCI), Inc. (NASDAQ: CSCI) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics in oncology, immunology and neurological disorders. Since its founding in 2014, COSCIENS has leveraged a proprietary platform for small molecules and biologics to identify drug candidates that modulate key disease pathways. The company’s pipeline spans several indications with unmet medical needs, reflecting a commitment to bringing first- or best-in-class therapies from research through clinical validation.
At the core of COSCIENS’s strategy is an integrated R&D operation that combines in silico modeling, high-throughput screening and translational biology. Lead candidates include a PD-1/PD-L1 inhibitor for solid tumors, a small-molecule kinase modulator targeting fibrotic pathways, and an antibody–drug conjugate for hematologic malignancies. Early-stage programs explore immunomodulatory agents for autoimmune conditions and neuroprotective compounds for Parkinson’s and Alzheimer’s disease. The company’s research sites in San Diego and Suzhou foster collaboration between U.S. and Asian scientific teams, accelerating timelines for preclinical studies and enabling parallel development across geographies.
In addition to its internal efforts, COSCIENS Biopharma maintains strategic partnerships with academic institutions and contract research organizations to expand its discovery engine and clinical trial capabilities. The company has initiated Phase I/II studies in North America and Asia, with plans to extend trials into Europe in the coming year. COSCIENS also emphasizes patient-centric development, engaging advocacy groups to shape trial design and ensure broad access to emerging therapies.
Leadership at COSCIENS Biopharma is headed by Chief Executive Officer Dr. Xiaoming Li, a veteran of biotech commercialization, and Chief Scientific Officer Dr. Mei Chen, whose expertise in immuno-oncology has guided the company’s translational programs. The management team’s collective experience spans drug discovery, regulatory affairs and global operations, positioning COSCIENS to advance its pipeline toward regulatory milestones and, ultimately, market launch.
